



## Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital

*Article 223-16 of the General Regulations of the Financial Markets Authority  
(AMF - Autorité des Marchés Financiers)*

**Lyon, France, July 5 2024 – 6:00 pm CET – [MaaT Pharma](#) (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies™ (MET) dedicated to enhancing survival of patients with cancer, today published the number of shares comprising the share capital and the total number of voting rights (Article L. 233-8 of the French Commercial Code (Code de commerce) and Article 223-16 of the General Regulations of French Autorité des Marchés Financiers (AMF)) on June 30, 2024.**

**Listing place:** Euronext Paris

**ISIN code:** FR0012634822

**Website:** [www.maatpharma.com](http://www.maatpharma.com)

Date	Total number of shares comprising the share capital	Total number of theoretical voting rights <sup>(1)</sup>	Total number of effective voting rights <sup>(2)</sup>
06/30/2024	13 918 369	13 918 369	13 891 440

*(1) In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.*

*(2) Effective voting rights correspond to the total number of voting rights that may be used at a General Meeting. The total number of effective voting rights is calculated without taking into account the shares with suspended voting rights.*

### About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the



microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

## Contacts

### MaaT Pharma – Investor Relations

Guillaume DEBROAS, Ph.D.

Head of Investor Relations

+33 6 16 48 92 50

[invest@maat-pharma.com](mailto:invest@maat-pharma.com)

### MaaT Pharma – Media Relations

Pauline RICHAUD

Senior PR & Corporate Communications Manager

+33 6 14 06 45 92

[media@maat-pharma.com](mailto:media@maat-pharma.com)

### Trophic Communications

Jacob VERGHESE or

Desmond JAMES

+49 151 7441 6179

[maat@trophic.eu](mailto:maat@trophic.eu)